MedTrace Logo

A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation

NCT01478529 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-06-27

No results posted yet for this study

Summary

A study to evaluate how much of the active compound of mirabegron comes into the blood circulation when given as a controlled-release pill as compared to given intravenously.

Conditions

  • Pharmacokinetics of Mirabegron
  • Bioavailability
  • Healthy Subjects

Interventions

DRUG

mirabegron OCAS

oral administration

DRUG

mirabegron

iv administration

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Clinical Study Manager · Astellas Pharma Europe B.V.

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01478529 on ClinicalTrials.gov